News about Food and Drug Administration, including commentary and archival articles published in The New York Times.

FDA mandates GLP-1 drug label updates for kidney injury risk due to dehydration, urging caution for users with gastrointestinal issues.

In characteristic style, Between the Eyes is annotated with scratchy fragments of text, owing as much to diagram labels and comic books as bathroom graffiti. "Between the eyes/Over our heads/Under ...

This shift is expected to accelerate following the FDA’s recent label expansion of Novo Nordisk’s Ozempic® to include CKD benefits, reinforcing the drug’s growing role in renal care.

Novo Nordisk’s type 2 diabetes drug Ozempic has expanded its label to include chronic kidney disease. The new FDA approval comes as makers of GLP-1 drugs work to expand the uses of these products.

(RTTNews) - Novo Nordisk A/S (NVO), Thursday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has supported label update for weight-loss drug ...

The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the label of its diabetes drug Ozempic, the Danish drugmaker said in a ...

Bagsværd, Denmark, 12 December 2024 - Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...

Bagsværd, Denmark, 12 December 2024 - Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...

Novo Nordisk received the go ahead to add a kidney disease–related expansion to Ozempic’s label in Europe. The Danish drugmaker said Thursday the European Medicines Agency (EMA) will allow a label ...